Immunovant Begin Period Cash Flow from 2010 to 2025
| IMVT Stock | USD 22.84 0.07 0.31% |
Begin Period Cash Flow | First Reported 2018-09-30 | Previous Quarter 714 M | Current Value 598.9 M | Quarterly Volatility 226.7 M |
Check Immunovant financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovant's main balance sheet or income statement drivers, such as Depreciation And Amortization of 358.1 K, Interest Expense of 0.0 or Selling General Administrative of 41.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.48. Immunovant financial statements analysis is a perfect complement when working with Immunovant Valuation or Volatility modules.
Immunovant | Begin Period Cash Flow | Build AI portfolio with Immunovant Stock |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.